Here's a concise, retail-friendly summary based on the investor presentation: **1. Business Performance:** Syngene's Q1 FY27 revenue from operations dropped 16% YoY to Rs 736 Cr.

Operating EBITDA margin was 12% (down from 24% in Q1 FY26), and PAT (before exceptional items) stood at Rs 1 Cr.

This was largely due to lower off-take from a key client and forex hedge losses, partly eased by cost-cutting efforts. **2. Growth Drivers or Strategy:** The company is advancing its three-pronged growth strategy: expanding integrated Discovery Services across various molecule types, boosting Large and Small Molecule CDMO capabilities, and leveraging Dedicated R&D Centers.

Operational excellence and robust ESG practices remain key strategic pillars. **3. Recent Developments:** Siddharth Mittal is the new MD & CEO.

Syngene partnered with BRIC-THSTI for clinical development and research.

They also enhanced Syn.AI, their AI platform, for faster drug discovery via gigascale screening and AI-driven molecule design.

The company was recognized among the "World's Most Sustainable Companies 2026." **4. Key Financial Metrics:** Q1 FY27 Revenue: Rs 736 Cr (-16% YoY). Operating EBITDA margin: 12%. PAT (before exceptional items): Rs 1 Cr. **5. Management Commentary / Outlook:** Management forecasts H1 FY27 degrowth but expects H2 momentum to improve.

This should lead to single-digit revenue degrowth for the full year, with EBITDA margins in the mid-20s.